AU2017348345B2 - ROR-gamma modulators - Google Patents

ROR-gamma modulators Download PDF

Info

Publication number
AU2017348345B2
AU2017348345B2 AU2017348345A AU2017348345A AU2017348345B2 AU 2017348345 B2 AU2017348345 B2 AU 2017348345B2 AU 2017348345 A AU2017348345 A AU 2017348345A AU 2017348345 A AU2017348345 A AU 2017348345A AU 2017348345 B2 AU2017348345 B2 AU 2017348345B2
Authority
AU
Australia
Prior art keywords
compound
formula
methyl
calkyl
hydroxypropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017348345A
Other languages
English (en)
Other versions
AU2017348345A1 (en
Inventor
Jason Harris
Raju Mohan
John Nuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Escalier Biosciences BV
Original Assignee
Escalier Biosciences BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escalier Biosciences BV filed Critical Escalier Biosciences BV
Publication of AU2017348345A1 publication Critical patent/AU2017348345A1/en
Application granted granted Critical
Publication of AU2017348345B2 publication Critical patent/AU2017348345B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Processing Of Color Television Signals (AREA)
  • Picture Signal Circuits (AREA)
AU2017348345A 2016-10-27 2017-10-27 ROR-gamma modulators Ceased AU2017348345B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413907P 2016-10-27 2016-10-27
US62/413,907 2016-10-27
PCT/US2017/058755 WO2018081558A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Publications (2)

Publication Number Publication Date
AU2017348345A1 AU2017348345A1 (en) 2019-05-30
AU2017348345B2 true AU2017348345B2 (en) 2022-01-27

Family

ID=62024021

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017348345A Ceased AU2017348345B2 (en) 2016-10-27 2017-10-27 ROR-gamma modulators

Country Status (14)

Country Link
US (5) US10905687B2 (enExample)
EP (1) EP3532062B1 (enExample)
JP (1) JP7027437B2 (enExample)
KR (1) KR102598775B1 (enExample)
CN (1) CN110139652B (enExample)
AU (1) AU2017348345B2 (enExample)
BR (1) BR112019008548A2 (enExample)
CA (1) CA3042080A1 (enExample)
ES (1) ES2928904T3 (enExample)
IL (1) IL266261B (enExample)
MX (1) MX392163B (enExample)
PH (1) PH12019500949A1 (enExample)
RU (1) RU2753490C2 (enExample)
WO (1) WO2018081558A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392163B (es) 2016-10-27 2025-03-21 Escalier Biosciences Bv Moduladores de ror gamma.
WO2019177997A1 (en) 2018-03-12 2019-09-19 Escalier Biosciences B.V. Spirocyclic ror-gamma modulators
US11230555B2 (en) 2018-03-12 2022-01-25 Escalier Biosciences B.V. Bicyclic RORγ modulators
JP2022554390A (ja) * 2019-11-05 2022-12-28 デルミラ インコーポレイテッド Ｒｏｒガンマｔ阻害剤およびその局所使用
CN115867267A (zh) * 2020-06-30 2023-03-28 德米拉公司 RORγt抑制剂和其局部用途
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140187554A1 (en) * 2011-05-16 2014-07-03 The Scripps Research Institute Modulators of the nuclear hormone receptor ror

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) * 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
AU2003280558A1 (en) * 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
HUP1100166A2 (en) * 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
JP2014526494A (ja) * 2011-09-19 2014-10-06 イーティーエイチ・チューリッヒ ＲＯＲγ修飾剤
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
CN107614062A (zh) * 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
MX392163B (es) 2016-10-27 2025-03-21 Escalier Biosciences Bv Moduladores de ror gamma.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140187554A1 (en) * 2011-05-16 2014-07-03 The Scripps Research Institute Modulators of the nuclear hormone receptor ror

Also Published As

Publication number Publication date
US20220175765A1 (en) 2022-06-09
WO2018081558A1 (en) 2018-05-03
KR102598775B1 (ko) 2023-11-03
KR20190096979A (ko) 2019-08-20
JP2019535813A (ja) 2019-12-12
MX392163B (es) 2025-03-21
CA3042080A1 (en) 2018-05-03
IL266261A (en) 2019-06-30
EP3532062A1 (en) 2019-09-04
RU2019115059A3 (enExample) 2020-12-18
US10905687B2 (en) 2021-02-02
AU2017348345A1 (en) 2019-05-30
PH12019500949A1 (en) 2019-08-05
US20210069182A1 (en) 2021-03-11
CN110139652A (zh) 2019-08-16
MX2019004973A (es) 2019-09-19
US20190269674A1 (en) 2019-09-05
CN110139652B (zh) 2022-10-11
BR112019008548A2 (pt) 2019-09-17
RU2753490C2 (ru) 2021-08-17
US20230277527A1 (en) 2023-09-07
ES2928904T3 (es) 2022-11-23
EP3532062A4 (en) 2020-04-15
RU2019115059A (ru) 2020-11-27
JP7027437B2 (ja) 2022-03-01
IL266261B (en) 2022-07-01
US20240216361A1 (en) 2024-07-04
EP3532062B1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
AU2017348345B2 (en) ROR-gamma modulators
CN102639496B (zh) 赖氨酸特异性脱甲基酶-1抑制剂及其应用
US11858900B2 (en) Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
CN113874021B (zh) Tyk2假激酶配体
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
US20200339547A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP3724163A1 (en) Fluorinated 4-(substituted amino)phenyl carbamate derivatives
JPH07503006A (ja) 認識力強化剤としてのジ置換多環式化合物
DE60130644T2 (de) R-2-(aminoaryl)-propionsäure-amide und ihre verwendung zur aktivierung von leukocyten
HK40012522A (en) Ror-gamma modulators
HK40012522B (en) Ror-gamma modulators
US20190112316A1 (en) Thiazolo[3,2-a] pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
CN120202198A (zh) 一种具有软药性质的硫醚类化合物、药物组合物及其用途
HK40066192A (zh) Tyk2假激酶配体
HK40066192B (zh) Tyk2假激酶配体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired